Obagi Medical Partners with Platinum Dermatology for Real-World Evidence on saypha MagIQ
Event summary
- Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has partnered with Platinum Dermatology Partners for the ALOHA Program to generate real-world evidence on Obagi saypha MagIQ.
- Platinum will evaluate the product across multiple practices and present initial findings at its September 2026 summit in Dallas.
- Obagi saypha MagIQ uses MACRO Core Technology for stable hyaluronic acid matrix, designed for natural-looking results.
The big picture
This collaboration aligns with the growing trend of leveraging real-world evidence to support aesthetic product launches, particularly in an industry where clinical validation is key. Waldencast’s strategic focus on scaling high-growth brands through partnerships underscores its broader ambition to build a global beauty and wellness platform.
What we're watching
- Clinical Validation
- How the real-world data from ALOHA will impact saypha MagIQ’s market adoption and differentiation.
- Scalability
- Whether Platinum Dermatology’s network can effectively scale Obagi’s product evaluation across 120+ locations.
- Competitive Positioning
- The pace at which Obagi can establish saypha MagIQ as a category leader in hyaluronic acid injectables.
Related topics